Specifically, Alcoceba et al. (Alcoceba et al., 2013) studied 250 DLBCL cases and 1940 controls, and revealed that patients receiving R-CHOP regimen and carrying the HLA-B44 supertype (and especially the HLA-B*18 polymorphism) had a worse 5-year PFS (54% vs. 71%, p-value = 0.019) and OS (71% vs. 92%, p-value = 0.001). Here, HLA-B is linked to diffuse large B-cell lymphoma.